Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C-Reference-Cited by-同舟云学术

Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C

Published:2016-10 Issue:16 Volume:76 Page:1567-1578
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Greig Sarah L.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-016-0648-2.pdf

Reference38 articles.

1. Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47–57.

2. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2016. http://www.hcvguidelines.org . Accessed 23 Sep 2016.

3. European Association for the Study of the Liver. EASL recommendations of treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.

4. Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43(12):1276–92.

5. Zhang J, Nguyen D, Hu KQ. Chronic hepatitis C virus infection: a review of current direct-acting antiviral treatment strategies. N Am J Med Sci. 2016;9(2):47–54.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel ProTide prodrugs of 5-fluoro-2′-deoxyuridine for the treatment of liver cancer;European Journal of Medicinal Chemistry;2023-11

2. The Burden of Inappropriate Prescriptions and Predictors for Hospitalized Patients with Liver Cirrhosis in Ethiopia;Hepatic Medicine: Evidence and Research;2023-09

3. An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats;Environmental Science and Pollution Research;2023-08-09

4. Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality;Pharmaceuticals;2023-02-22

5. Direct Antiviral Agents for Hepatitis C;New Antimicrobials: For the Present and the Future;2023